Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01592227 · ClinicalTrials.gov registry record · Phase 1
A Study to Compare Two Paracetamol Formulations.
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT01592227 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 30 participants.
The verdict
NCT01592227, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
A pharmacokinetic study investigating the rate and extent of absorption of paracetamol and an adjuvant from two different paracetamol formulations.
Interventions
- DRUG Experimental paracetamol formulation
- DRUG Marketed paracetamol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2009-12 |
| Est. Completion | 2009-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01592227
The ClinicalTrials.gov registry entry for NCT01592227 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Experimental paracetamol formulation is the first listed.
NCT01592227 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01592227 about?
NCT01592227 is a clinical study titled "A Study to Compare Two Paracetamol Formulations.". A pharmacokinetic study investigating the rate and extent of absorption of paracetamol and an adjuvant from two different paracetamol formulations.
What is the current status of trial NCT01592227?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2009-12. Estimated completion is 2009-12.
What interventions are being tested in trial NCT01592227?
The interventions under investigation include: Experimental paracetamol formulation (DRUG), Marketed paracetamol (DRUG).
Who is sponsoring clinical trial NCT01592227?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.